A manic episode is an acute affective syndrome characterized by a pathological change in mood associated with an abnormal increase in activity or energy and disturbances of sleep, thought, speech, self-esteem, attention, psychomotor activity, and behavior. Severity is sufficient to cause marked personal, social, or occupational impairment, require intensive treatment or hospitalization to prevent harm, or be accompanied by delusions or hallucinations.
The episode is one of the main defining elements of bipolar I disorder, but it should not be confused with the disorder itself. According to DSM-5-TR, the lifetime presence of at least one manic episode not attributable to substances or medical conditions is sufficient to diagnose bipolar I disorder, regardless of whether major depressive episodes have occurred. In ICD-11 as well, a history of at least one manic or mixed episode is the fundamental requirement for the diagnosis of bipolar I disorder.
DSM-5-TR requires, in its initial criterion, a distinct period of at least one week during which abnormally elevated, expansive, or irritable mood and abnormally increased activity or energy are present for most of the day nearly every day; the duration threshold is not required when severity necessitates hospitalization. The ICD-11 CDDR similarly requires a duration of at least one week, unless shortened by treatment, but uses a formulation less rigidly based on a predetermined number of additional symptoms.
Epidemiological estimates should refer to the disorder and not be improperly presented as the prevalence of an individual episode. In the World Mental Health Surveys, the pooled lifetime prevalence of bipolar I disorder was 0.6%; in the US National Comorbidity Survey Replication it was 1.0%. The differences reflect different populations, methods, and definitions and do not directly describe the probability of experiencing a specific manic episode.
Onset of bipolar disorder frequently occurs between adolescence and young adulthood, but a first manic episode may occur at any age. Late onset, especially when clearly atypical relative to previous history, should heighten attention to secondary medication-related, neurological, endocrine, or toxicological causes.
There is no single etiological cause of primary mania. In bipolar I disorder, the episode emerges from a complex interaction among genetic vulnerability, neurobiological regulation, circadian rhythms, and environmental factors. Etiological causes can instead be identified in some mania-like syndromes secondary to substances, medications, or medical conditions, which should be classified appropriately when a convincing pathophysiological relationship exists.
Bipolar disorder is highly polygenic. Genome-wide studies involving tens of thousands of cases have identified numerous susceptibility loci and confirmed that risk derives from the combination of many genetic variants, none of which is sufficient to determine the disorder. Findings involve neuronal and synaptic pathways and show partial genetic overlap with other psychiatric disorders.
Family history is therefore an important risk factor but does not inevitably determine the onset of mania. People without a known family history can develop bipolar disorder, and many relatives of patients will never develop the illness. Currently available genetic tests do not permit an individual clinical diagnosis of mania.
Regulation of sleep and circadian rhythms plays a central role. Sleep reduction and disruption of routines may precede episode onset, while decreased need for sleep is simultaneously one of its cardinal symptoms. Sleep loss can therefore act both as an early sign and as a possible amplifier of destabilization.
Dopaminergic neurotransmission has long been implicated in the pathophysiology of mania. Increased salience attributed to stimuli and heightened reward sensitivity may contribute to grandiosity, hyperactivity, and impulsive behavior, while the efficacy of dopamine antagonists or modulators supports the relevance of this system. There is, however, no evidence of a simple uniform “dopamine excess” in all patients.
Glutamate and GABA, serotonergic and noradrenergic systems, intracellular second messengers, mitochondrial function, calcium regulation, and mechanisms of neuroplasticity have also been implicated. Response to lithium, anticonvulsants, and antipsychotics involves multiple molecular pathways and confirms that control of the episode does not depend on a single biological target.
Neuroendocrine and immunological studies describe average alterations in stress-axis function, inflammatory markers, and oxidative stress across different phases of bipolar disorder. These data are heterogeneous and influenced by numerous confounding factors. There are no cortisol, cytokine, or other marker values that can be used to diagnose mania.
ENIGMA neuroimaging analyses have documented average structural differences in cortical and subcortical regions in bipolar disorder. The variations are distributed, generally modest in magnitude, and nonspecific. A normal magnetic resonance scan therefore does not exclude mania, and an abnormal scan does not demonstrate it.
Network models assign particular importance to the interaction among brain systems involved in reward, salience, and prefrontal control. Greater motivational drive associated with reduced inhibition may contribute to increased goal-directed activity and impaired evaluation of consequences, while instability of emotional circuits may favor rapid shifts among euphoria, irritability, and dysphoria.
Stimulant substances, including cocaine and amphetamines, can produce clinical syndromes similar to mania by increasing catecholaminergic neurotransmission. Intoxication and withdrawal must be reconstructed temporally because correct diagnosis distinguishes a substance-induced syndrome from a spontaneous episode.
Medications can also precipitate mania-like syndromes. Corticosteroids, dopaminergic drugs, and antidepressants are clinically relevant examples, but risk depends on individual susceptibility and does not imply that every activation symptom has the same origin. A detailed history of treatment changes is therefore mandatory.
In DSM-5-TR, a full manic syndrome that emerges during antidepressant treatment and persists at a syndromic level beyond the physiological effect of the therapy may be considered a true manic episode. Interpretation nevertheless requires that the criteria for the entire episode truly be met, rather than merely the appearance of agitation or insomnia.
Neurological diseases can cause secondary mania. Conditions to consider, especially with atypical onset, include focal brain lesions, traumatic brain injury, cerebrovascular disease, neoplasms, epilepsy, and neurodegenerative or demyelinating diseases. The likelihood of an organic cause increases when neurological deficits, cognitive decline, or absence of a previous affective history coexist.
Among endocrine conditions, thyrotoxicosis and other systemic abnormalities may contribute to agitation and activation syndromes. Somatic symptoms, objective abnormalities, and the clinical context guide test selection; it is not appropriate to attribute mania to an endocrine disease simply because a laboratory parameter is marginally abnormal.
The postpartum period is a phase of particular vulnerability in predisposed individuals. The combination of abrupt biological changes, reduced sleep, and bipolar vulnerability may promote manic or psychotic episodes. The onset of mania or psychosis after childbirth is a potentially urgent presentation for the safety of both mother and newborn.
Stress, life events, and changes in social rhythms may contribute to onset without being necessary causes. The most appropriate pathogenetic model is therefore dynamic: a pre-existing biological vulnerability interacts with sleep, medications, substances, and the environment until a clinical threshold is crossed beyond which regulation of mood and activity becomes pathological.
History-taking can be difficult because insight is frequently reduced during mania. The patient may consider themselves exceptionally healthy, productive, or lucid and view family members and clinicians as obstacles to their plans. Obtaining information from people who know the patient well therefore has particularly high diagnostic and safety value.
Mood may be euphoric, expansive, or predominantly irritable. Euphoria may manifest as excessive enthusiasm, unrealistic optimism, and inappropriate familiarity; irritability emerges especially when the patient is contradicted or obstructed and may be accompanied by verbal or behavioral aggression.
Increased energy and activity, together with mood disturbance, form the syndromic core. The person may start numerous projects, organize activities incessantly, stay out all night, intensify work or social activity to an extreme degree, and show obvious difficulty stopping.
Decreased need for sleep may be extreme. The patient sleeps only a few hours or almost not at all without experiencing the expected fatigue and uses the extra time for new activities. As the episode continues, prolonged sleep deprivation may contribute to disorganization and worsening symptoms.
Self-esteem may develop into pathological grandiosity. The patient may attribute unrealistic professional, artistic, financial, religious, or political abilities to themselves, undertake ventures clearly beyond their competence, or claim special relationships with public figures.
When grandiosity reaches delusional intensity, the presentation has psychotic features. The patient may be convinced of possessing supernatural powers, nonexistent wealth, or an exceptional role. Persecutory delusions may occur especially when others attempt to limit their activities.
Speech often becomes pressured, rapid, and difficult to interrupt. Volume may increase, the patient shifts topics quickly, and may produce puns or sound-based associations. In more severe presentations, flight of ideas may progress toward thought that is difficult to follow.
Distractibility interferes with the ability to sustain attention. The patient responds to irrelevant stimuli, continually interrupts activities, and may move from one task to another. The combination of accelerated thinking and distractibility can drastically reduce actual effectiveness despite a subjective sense of exceptional productivity.
Behavioral activation may involve sexuality, spending, investments, travel, gambling, driving, entrepreneurial activities, and substance use. The distinguishing feature is reduced ability to evaluate negative consequences in the presence of a strong drive to act.
Social disinhibition may lead to inappropriate familiarity, invasion of personal space, sexual comments, provocative behavior, or rule violations. These manifestations may result in conflicts, legal complaints, or situations of vulnerability and exploitation.
Agitation may become very intense and develop into a clinical emergency when there is imminent risk of harm. Intervention should keep safety as the primary objective, using de-escalation techniques and the least restrictive level of intervention compatible with the clinical picture.
Psychotic symptoms may include delusions and hallucinations. Their presence is compatible with mania and is one of the features that clearly distinguish a manic episode from hypomania. Content may be mood-congruent or mood-incongruent.
Mixed features are clinically important. Depressed mood, anhedonia, guilt, hopelessness, and suicidal thoughts may coexist with grandiosity, acceleration, and increased energy. These presentations are generally more complex and require particularly careful risk assessment.
Catatonia may accompany a mood episode and should be recognized as a specific psychomotor syndrome. Stupor, mutism, negativism, posturing, stereotypy, agitation not influenced by stimuli, echolalia, and echopraxia require a separate assessment because they may necessitate urgent treatment.
The mental status examination evaluates appearance, behavior, psychomotor activity, speech, mood, affect, thought process and content, perception, cognition, insight, and judgment. The patient may present in conspicuous clothing, hyperactive, intrusive, highly talkative, and with little awareness of the consequences of their behavior.
Assessment must directly include the risk of suicide, self-harm, and harm to others. The idea that a manic person cannot be suicidal because they are energetic or euphoric is incorrect, especially in mixed presentations or during rapid changes in affective state.
The ability to eat, drink, and rest, vulnerability to exploitation, care of children or other dependents, access to money, dangerous means, and vehicles should also be considered. The severity of mania is therefore measured through concrete consequences as well as through the intensity of euphoria.
The diagnosis of mania is clinical and simultaneously requires identification of the syndrome, assessment of its severity, exclusion of secondary causes, and longitudinal reconstruction of the mood history. No biomarker, laboratory test, or instrumental finding independently confirms the episode.
The initial assessment must immediately establish whether the patient requires an urgent setting. Uncontrollable agitation, severe psychosis, inability to meet basic needs, risk to self or others, and severe disorganization may necessitate intensive treatment or hospitalization.
According to DSM-5-TR, official diagnostic criteria exist for a manic episode.
According to DSM-5-TR, a distinct period of abnormally and persistently elevated, expansive, or irritable mood associated with abnormally and persistently increased activity or energy is required, present for most of the day nearly every day for at least one week, unless hospitalization is necessary, with at least three of the following symptoms or at least four if the mood is exclusively irritable.
The syndrome must be sufficiently severe to cause marked social or occupational impairment, require hospitalization to prevent harm, or be accompanied by psychotic features. This severity requirement is what structurally distinguishes mania from hypomania.
The presentation must not be attributable to the physiological effects of a substance or another medical condition. In the DSM, a full manic syndrome arising during antidepressant treatment that persists beyond the direct physiological effect of the treatment may be considered evidence of a manic episode.
The ICD-11 CDDR requires an extreme mood state characterized by euphoria, irritability, or expansiveness and a concomitant increase in activity or subjective experience of increased energy, present for most of the day nearly every day for at least one week unless shortened by treatment. Several manic symptoms must be present, but ICD-11 does not impose the rigid DSM threshold of three or four additional symptoms.
Characteristic ICD-11 manifestations include increased talkativeness or pressured speech, flight of ideas or racing thoughts, increased self-esteem or grandiosity, decreased need for sleep, distractibility, impulsive or risky behavior, and increased sexuality, sociability, or goal-directed activity.
Severity must cause significant impairment, a need for intensive treatment to prevent harm, or the presence of delusions or hallucinations. In ICD-11, when the patient has previously experienced manic or mixed episodes, the one-week threshold is not mandatory for classifying a new manic episode if all other requirements are met.
Once primary mania has been established, the next nosographic step is the diagnosis of bipolar I disorder. Previous depressive episodes, hypomania, mixed episodes, psychosis, hospitalizations, and treatments should be reconstructed, but a history of depression is not required to diagnose bipolar I disorder.
The presence of mixed features should be systematically investigated. Concurrent depressive symptoms do not exclude mania; in the DSM they may permit use of the with mixed features specifier, while ICD-11 also includes the distinct category of mixed episode when its requirements are met.
The medication and toxicological history should include antidepressants, corticosteroids, dopaminergic drugs, prescribed stimulants, recreational substances, supplements, and recent treatment changes. Collateral information is often essential when insight is reduced.
First-line medical investigations are targeted. VA/DoD includes complete blood count, metabolic panel, thyroid function, and toxicology screening among tests that are frequently useful in the work-up, to be supplemented according to the history and physical examination. Pregnancy testing, ECG, and other investigations may be necessary particularly in relation to the planned treatment.
An abnormal TSH does not by itself demonstrate that mania is secondary to thyroid dysfunction. Likewise, a positive toxicology result must be interpreted together with the timeline. Causal diagnosis requires consistency between exposure and symptom onset.
Neuroimaging and EEG are reserved for cases in which the history or neurological examination suggests brain disease. A first episode at an unusually advanced age, focal deficits, seizures, recent trauma, cognitive decline, or a neurologically atypical course are indications to broaden the investigation.
Hypomania is the main syndromic differential diagnosis. The phenomenology is similar, but the absence of marked impairment, intensive treatment, and psychosis keeps the presentation within the hypomanic domain. If psychosis occurs, the presentation cannot be classified as hypomania.
Stimulant intoxication can mimic mania almost completely. Withdrawal, medications, and delirium must also be distinguished through chronology, fluctuations in consciousness, somatic and toxicological findings, and response to discontinuation of the exposure.
In psychotic disorders, agitation, grandiosity, and disorganization may occur. Longitudinal assessment of the relationship between psychosis and mood syndromes is decisive. Psychosis occurring exclusively during mania is compatible with bipolar I disorder with psychotic features.
ADHD presents with hyperactivity, impulsivity, distractibility, and talkativeness, but these characteristics form a persistent pattern beginning during the developmental period rather than a clear episodic change accompanied by shifts in mood and need for sleep.
In personality disorders, affective instability may be intense, but the pattern is generally chronic and more reactive to interpersonal circumstances. A diagnosis of mania instead requires a complete episodic syndrome with increased energy and activity.
Diagnostic assessment therefore concludes not with simple symptom counting but with a formulation specifying severity, psychosis, mixed or catatonic features, immediate risk, secondary causes, comorbidities, and the history of previous episodes.
A manic episode frequently requires prompt specialist treatment. Initial priorities are safety, control of agitation, restoration of sleep, reduction of stimulation, identification of precipitating substances or medications, and initiation of effective antimanic therapy.
Hospitalization should be considered when risk cannot be managed safely in a less restrictive setting, in the presence of severe psychosis, dangerous behavior, extreme impairment of judgment, inability to meet basic needs, or a need for intensive treatment.
If the patient is taking an antidepressant, guidelines generally recommend discontinuing it when mania develops, using a method appropriate to the individual drug and clinical context. Substances and stimulants contributing to activation should also be stopped or reduced when possible.
There is no perfect overlap among the pharmacological hierarchies of major guidelines. CANMAT/ISBD 2018 considers lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine first-line monotherapies for acute mania, with selection based on clinical characteristics, previous responses, and tolerability.
CANMAT also includes among first-line strategies several combinations of lithium or divalproex with atypical antipsychotics such as quetiapine, aripiprazole, risperidone, or asenapine. Combination therapy may be particularly useful in more severe presentations or when a rapid response is needed, at the cost of greater exposure to adverse effects.
NICE, updated in 2025, uses a different sequence and recommends that a person who develops mania or hypomania and is not already taking an antipsychotic or mood stabilizer be offered haloperidol, olanzapine, quetiapine, or risperidone. If ineffective or poorly tolerated, another antipsychotic is considered, followed by lithium and then valproate when appropriate.
Differences among guidelines do not necessarily represent scientific contradiction: they arise from different evidence-grading methods, healthcare systems, safety profiles, and treatment sequences. Therapy should therefore be individualized rather than reduced to a single universal ranking.
Lithium is particularly important in classic mania and prevention of recurrences. Its use requires monitoring of serum lithium levels, renal and thyroid function, and attention to interactions with drugs that alter renal lithium elimination.
Valproate is effective in mania, including some presentations with mixed features, but its use is strongly constrained by reproductive restrictions. In bipolar disorder it is contraindicated during pregnancy in the European Union; in women of childbearing potential, stringent pregnancy-prevention measures and specialist reassessment are required. Since 2024, specific precautions have also been introduced for male patients.
Antipsychotics have a central role especially when psychosis, agitation, or a need for rapid control of activation is present. Selection should consider extrapyramidal effects, akathisia, sedation, weight gain, dyslipidemia, glycemic changes, prolactin effects, and cardiovascular risk.
Benzodiazepines may be used for short periods as supportive treatment for agitation and insomnia, but they are not the fundamental treatment of bipolar disorder and should be used with assessment of sedation, dependence, and interactions.
The presence of mixed features modifies treatment choice. CANMAT/ISBD notes that atypical antipsychotics and divalproex may be particularly useful in these presentations, while antidepressants require particular caution. The specific evidence for mixed states is considered separately from pure mania.
Electroconvulsive therapy is an evidence-based treatment to consider in severe mania when a rapid response is needed, in pharmacoresistant cases, when there has been a previous favorable response, or when adverse effects preclude adequate pharmacotherapy. It is also particularly relevant in the presence of catatonia.
Catatonia requires a specific strategy. Benzodiazepines, particularly lorazepam, and ECT are the treatments with the strongest support, while dehydration, malnutrition, thromboembolism, infections, and complications of immobility must simultaneously be prevented.
During the acute phase, an environment with reduced stimulation, clear routines, and limitation of opportunities for dangerous behavior is useful. Environmental measures do not replace pharmacotherapy in severe cases but may reduce escalation of activation.
Once remission is achieved, treatment shifts to relapse prevention. Lithium, quetiapine, divalproex, aripiprazole, asenapine, and other strategies have differing maintenance evidence, and selection depends mainly on the drug effective during the acute phase, predominant polarity, and tolerability.
Psychosocial interventions such as psychoeducation, cognitive behavioral therapy, family interventions, and interpersonal and social rhythm therapy may be added to pharmacological maintenance treatment. Their goals include adherence, recognition of prodromes, sleep regularization, and management of destabilizing factors.
The prognosis of the acute episode is often favorable in terms of symptomatic remission when treatment is timely, but bipolar I disorder has a strong tendency to recur. Remission of mania therefore does not mean the end of the illness.
Residual symptoms, substance use, poor adherence, a high number of previous episodes, mixed features, and comorbidity may be associated with a more complex course. Prognosis should be formulated individually and reassessed over time.
Outcome assessment should include recovery of functioning. After euphoria or agitation resolves, financial, legal, relational, and occupational consequences may persist and require specific interventions.
Mania can produce severe consequences through the combination of increased energy, impaired judgment, impulsivity, and poor insight. Complications are not simply “more intense symptoms” but clinical, social, and medical consequences arising from the episode.
Financial behavior may lead to financial ruin, debt, disadvantageous contracts, or irrational investments. Grandiosity increases the belief that the person can control risks that under normal conditions would be recognized as excessive.
Sexual disinhibition may result in unprotected sex, sexually transmitted infections, unplanned pregnancies, and relational consequences. Vulnerability may also expose the patient to exploitation or violence by others.
Reckless driving, excessive speed, risky activities, and reduced perception of danger increase the likelihood of accidents and injuries. Access to vehicles or other dangerous means should be considered in the safety assessment.
Irritability and disinhibition may cause conflicts, aggression, and legal consequences. Agitation does not automatically imply violence, but a history of aggression, substance use, and severe disorganization increases the need for structured risk management.
Prolonged reduction in sleep and incessant activity may lead to physical exhaustion, dehydration, reduced food intake, and worsening of pre-existing medical illnesses. In severe cases, the person may be unable to care for basic needs.
Psychosis is not properly a separate complication of the episode but a possible feature of mania. It may nevertheless amplify consequences through grandiose or persecutory delusions, disorganized behavior, and greater difficulty accepting treatment.
Mixed features may be associated with a particularly dangerous combination of hopelessness and activation. Increased energy and impulsivity may coexist with suicidal ideation, making repeated safety assessments necessary.
Suicide risk does not necessarily end when mania subsides. A subsequent depressive phase, awareness of the consequences of the episode, or rapid mood fluctuations may change risk over time.
Use or increased use of alcohol and substances can complicate the episode, reduce adherence, increase impulsivity and aggression, and hinder distinction between primary and induced symptoms.
Catatonia associated with a mood disorder may cause medical complications of immobility such as thromboembolism, pressure injuries, dehydration, malnutrition, and infections. Forms with autonomic instability require urgent treatment.
Occupational and academic consequences may include job loss, suspension from studies, professional conflicts, and reputational damage. Even after remission, a gradual process of functional recovery may be necessary.
Family relationships may experience persistent effects as a consequence of aggression, infidelity, spending, socially inappropriate behavior, or decisions made during the episode. Family intervention may therefore have a rehabilitative as well as preventive role.
An additional problem is treatment nonadherence, promoted by perceiving mania as a positive state or by lack of illness awareness. Self-discontinuation of treatment increases relapse risk and should be addressed through shared decision-making and psychoeducation.
Finally, treatments themselves may cause metabolic, neurological, renal, thyroid, or reproductive adverse events. Preventing complications of mania therefore requires balancing rapid control of the episode against systematic monitoring of treatment safety.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.